In vitro fosfomycin activity in vancomycin-resistant Enterococcus faecalis

Brazilian Journal of Infectious Diseases

Volumn 13, Issue 2, 2009, Pages 123-124

  Superti, Silvana ^a   Dias, Cícero Armídio Gomes ^b   D'Azevedo, Pedro Alves ^a,b  

^a Post Graduation Program in Pathology of Health Sciences   (Brazil)

^b University of Health Sciences of Porto Alegre   (Brazil)

Author keywords

Enterococcus faecalis; Fosfomycin; Vancomycin resistance; VRE

Indexed keywords

FOSFOMYCIN;

AGAR DIFFUSION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BRAZIL; DRUG ACTIVITY; ENTEROCOCCUS FAECALIS; EPSILOMETER TEST; HOSPITAL; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; ENTEROCOCCUS FAECALIS; FOSFOMYCIN; HUMANS; MICROBIAL SENSITIVITY TESTS; VANCOMYCIN RESISTANCE;

EID: 76749155574     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1413-867020090002000010     Document Type: Article

References (15)

1. th ed., ASM Press, Washington, D.C, 2002.
2. Bonten M.J.M.,Willens R., Weistein R.A. Vancomycin-resistant enterococci: why are they here, and where do they come from. Lancet 2001;1:314-25.
3. th ed, ASM Press, Washington, D.C, 2002.
4. Patel R. Clinical impact of vancomycin-resistant enterococci. J Antimicrob Chemother 2003;51:13-21.
5. d'Azevedo P.A., Kacman S.B., Schmalfuss T., et al. Primeiro caso de enterococo resistente à vancomicina isolado em Porto Alegre, RS. J Bras Patol Med Labor 2000;36(3):258.
6. Gobernado M. Fosfomicina. Rev Esp Quimioterap 2003;16:15-40.
7. th ed, ASM Press, Washington, D.C, 2007.
8. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Information Supplement M-100-516. 2006. CLSI, Wayne, PA, USA.
9. Kauffmann C.A. Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections. J Antimicrob Chemother 2003;51:23-30.
10. Noskin G.A. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005;41:S303-14.
11. Johnson A.P., Tyssal L., Stockdale M.W., et al. Emerging Linezolid-Resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive Care Unit. Eur J Clin Microbiol 2002; 21:751-4.
12. Allerberger F., Klare I. In vitro activity of fosfomycin against vancomycin-resistant enterococci. J Antimicrob Chemother 1999;43:211-7.
13. Perri M.B., Hershberger E., Ionescu M., et al. In vitro susceptibility of vancomycin resistant enterococci (VRE) to fosfomycin. Diag Microb Infect Dis 2002;42:269-71.
14. Abdulia F.E., Abdulia E.M. Antibiotic options for Enterococcus faecalis infections. Pak J Med Sci 2006;22(3):286-90.
15. Shresta N.K., Amuh D., Goldman M.P., et al. Treatment of a complicated vancomycin resistant enterococcal urinary tract infection with fosfomycin. Infect Dis Clin Prac 2000;9:368-71.